Serum @entity6239 (AG) and @entity69925 ( @entity69926 ) concentrations were measured by high pressure liquid chromatography (HPLC) in 24 postmenopausal @entity1 with @entity0 receiving increasing doses of oral AG. @entity1 received 62.5 mg b.d., 125 mg b.d., 250 mg b.d., and 500 mg b.d. of AG alone, and 500 mg b.d. of AG combined with @entity701 (HC) 20 mg b.d. Dose was increased at monthly intervals. Each dose increment was accompanied by a significant rise in serum AG and @entity69926 levels (P less than 0.05). The addition of HC to the dose of 500 mg b.d. of AG did not alter serum AG or @entity69926 concentrations significantly. Although serum AG and @entity69926 levels appeared to increase linearly with dose, serum @entity69926 increased significantly more slowly, leading to a fall in the @entity69926 :AG ratio during therapy. The @entity69926 :AG ratio appeared to stabilise only after about 6 months of treatment.

Observations on the pharmacokinetics of low dose @entity6239 in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'Patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['advanced breast cancer'] @entity69925 :: ('MESH:C036163', 'Chemical') :: ['N-acetylaminoglutethimide'] @entity69926 :: ('CHEBI:44337', 'Chemical') :: ['NAG'] @entity6239 :: ('MESH:D000616', 'Chemical') :: ['aminoglutethimide'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['hydrocortisone']
@entity0 :: (MESH:D001943,Disease) :: ['advanced breast cancer']
